Cargando…

Beta3-Adrenoceptor Agonists: Possible Role in the Treatment of Overactive Bladder

In the present review article, we present an overview of beta-adrenoceptor (β-AR) subtype expression at the mRNA and receptor protein levels in the human detrusor, the in vitro and in vivo bladder function of the β3-AR, the in vivo effect of β3-AR agonists on detrusor overactivity in animal models,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Igawa, Yasuhiko, Aizawa, Naoki, Homma, Yukio
Formato:	Texto
Lenguaje:	English
Publicado:	The Korean Urological Association 2010
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016425/ https://www.ncbi.nlm.nih.gov/pubmed/21221199 http://dx.doi.org/10.4111/kju.2010.51.12.811

Ejemplares similares

Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting
por: Huang, Chiung-Kun, et al.
Publicado: (2020)

Urinary beta 3-adrenoceptor as a diagnostic biomarker for overactive bladder in women
por: Liang, Ching-Chung, et al.
Publicado: (2023)

Characteristics of the mechanosensitive bladder afferent activities in relation with microcontractions in male rats with bladder outlet obstruction
por: Aizawa, Naoki, et al.
Publicado: (2017)

Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2014)

Pathophysiology of the underactive bladder
por: Aizawa, Naoki, et al.
Publicado: (2017)

Overactive Bladder: Pathophysiology, Diagnostics, and Therapies
por: Heesakkers, John P. F. A., et al.
Publicado: (2011)

Attenuated lipopolysaccharide-induced inflammatory bladder hypersensitivity in mice deficient of transient receptor potential ankilin1
por: Kamei, Jun, et al.
Publicado: (2018)

Age-related changes in function and gene expression of the male and female mouse bladder
por: Kamei, Jun, et al.
Publicado: (2018)

On the Site and Mechanism of Action of β(3)-Adrenoceptor Agonists in the Bladder
por: Andersson, Karl Erik
Publicado: (2017)

Pharmacokinetics of Mirabegron, a β(3)-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy Japanese Male Subjects: Results from Single- and Multiple-Dose Studies
por: Iitsuka, Hiromi, et al.
Publicado: (2013)

Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists
por: Okui, Nobuo
Publicado: (2019)

A Clinician’s Perspective on the Mechanism of β(3)-Adrenoceptor Agonists in the Bladder
por: Lee, Tack
Publicado: (2017)

Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review
por: Wani, Mudassir M., et al.
Publicado: (2021)

Mirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
por: Bhide, Alka A, et al.
Publicado: (2012)

Korean Version of the Overactive Bladder Symptom Score Questionnaire: Translation and Linguistic Validation
por: Jeong, Seong Jin, et al.
Publicado: (2011)

Role of fesoterodine in the treatment of overactive bladder
por: Mansfield, Kylie J
Publicado: (2009)

Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy
por: Shin, Jung Hyun, et al.
Publicado: (2017)

Roles of Beta2- and Beta3-Adrenoceptor Polymorphisms in Hypertension and Metabolic Syndrome
por: Masuo, Kazuko
Publicado: (2010)

Characterization of the role of HCN channels in β3-adrenoceptor mediated rat bladder relaxation
por: Kashyap, Mahendra, et al.
Publicado: (2015)

Long‐term safety and efficacy of antimuscarinic add‐on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study)
por: Yamaguchi, Osamu, et al.
Publicado: (2018)

The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease()
por: Dale, Philippa R, et al.
Publicado: (2014)

Cardiovascular safety of vibegron, a new β3‐adrenoceptor agonist, in older patients with overactive bladder: Post‐hoc analysis of a randomized, placebo‐controlled, double‐blind comparative phase 3 study
por: Yoshida, Masaki, et al.
Publicado: (2021)

Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonist
por: Beeh, Kai M, et al.
Publicado: (2010)

Treatment of Hypertension with Beta-Adrenoceptor Blocking Drugs
por: Bai, Tony R., et al.
Publicado: (1982)

Role of KIT-Positive Interstitial Cells of Cajal in the Urinary Bladder and Possible Therapeutic Target for Overactive Bladder
por: Kubota, Yasue, et al.
Publicado: (2011)

Overactive bladder
por: Wallace, Karen M., et al.
Publicado: (2015)

Clinical Utility of β(3)-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations
por: Krhut, Jan, et al.
Publicado: (2022)

The Urobiome and Its Role in Overactive Bladder
por: Bae, Sangrak, et al.
Publicado: (2022)

β(2)‐Adrenoceptor agonist activity of higenamine
por: Hudzik, Thomas J., et al.
Publicado: (2021)

Transdermal oxybutynin in the treatment of overactive bladder
por: Davila, G Willy
Publicado: (2006)

OnabotulinumtoxinA for the treatment of overactive bladder
por: Cox, Lindsey, et al.
Publicado: (2014)

Individualizing medical treatment of overactive bladder
por: Kuo, Hann-Chorng
Publicado: (2018)

Beta-Adrenoceptor Blocking Drugs and the Elderly
por: Wilkins, M. R., et al.
Publicado: (1984)

Uses of Beta-Adrenoceptor Blocking Drugs
por: Prichard, B. N. C., et al.
Publicado: (1976)

The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD)
por: Sagvolden, Terje
Publicado: (2006)

Postmenopausal overactive bladder
por: Tomaszewski, Jacek
Publicado: (2014)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
por: Al-Ghazo, Mohammed A., et al.
Publicado: (2011)

Alpha-2 adrenoceptor agonists and sepsis: improved survival?
por: Quintin, Luc
Publicado: (2010)

Paradoxical bronchoconstriction caused by β(2)-adrenoceptor agonists
por: Ayed, Khadija, et al.
Publicado: (2020)

Oxybutynin topical gel in the treatment of overactive bladder
por: Davila, G Willy
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_v0l15qlu22cvilpea8nnfel38e